Magnetic nanoparticles (MNPs) based hyperthermia therapy offers a promising cancer treatment owing to its high controllability and safety nature [1].However, several fundamental challenges remain regarding the clinical translation of existing MNPs [2].For example, the undesirable magnetic-to-thermal conversion efficiency would require high dosage of MNPs that may provoke harmful side effects.Ferrimagnetic materials with unfavorable stability could form particle aggregation under alternative magnetic field (AMF) and are therefore not suitable for clinical use.To address these challenges, extensive endeavors have been devoted to improving the performance of MNPs in magnetic hyperthermia therapy, and major effects were mainly centered on the chemically synthesized MNPs [3].Despite some enhancements in thermal conversion, other critical concerns (e.g., instability and potential toxicity) still remain, limiting the performance of the conventional MNPs [4].